Evidence map›Paper›PMID 35197976›Full record

ArticleFrontiers in immunology2022

Mucosal Vaccination With Recombinant

Junfei Wei, Venkatesh L Hegde, Ananta V Yanamandra, Madison P O'Hara, Brian Keegan, Kathryn M Jones, Ulrich Strych, Maria Elena Bottazzi, Bin Zhan, K Jagannadha Sastry and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Development of semisynthetic saponin immunostimulants.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2024
    Review
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Junfei WeiTexas Children's Hospital Center for Vaccine Development, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, United States.
Venkatesh L HegdeDepartment of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Ananta V YanamandraDepartment of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Madison P O'HaraDepartment of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Brian KeeganTexas Children's Hospital Center for Vaccine Development, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, United States.
Kathryn M JonesTexas Children's Hospital Center for Vaccine Development, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, United States.
Ulrich StrychTexas Children's Hospital Center for Vaccine Development, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, United States.
Maria Elena BottazziTexas Children's Hospital Center for Vaccine Development, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, United States.
Bin ZhanTexas Children's Hospital Center for Vaccine Development, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, United States.
K Jagannadha SastryDepartment of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Peter J HotezTexas Children's Hospital Center for Vaccine Development, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, United States.
Texas Children's Hospital · USThe University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · US

Funding

A novel mucosal trichuriasis vaccine for Th2 immune protection.R21AI144555 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI HOTEZ, PETER J, SASTRY, JAGANNADHA K · 2019 to 2020
$454k
NIAID NIH HHS R21 AI144555
6 · The paper itself

Abstract

Trichuriasis is one of the most common neglected tropical diseases of the world's poorest people. A recombinant vaccine composed of

Indexed as

Adjuvants, ImmunologicAdministration, IntranasalAnimalsAntibody FormationCD8-Positive T-LymphocytesFemaleImmunity, CellularImmunity, MucosalImmunizationImmunoglobulin AImmunoglobulin GMiceMice, Inbred AKRMice, Inbred BALB CMucous MembraneTh1 CellsAdjuvants, ImmunologicImmunoglobulin AImmunoglobulin GVaccines, Syntheticadjuvantsintranasal immunizationmucosal immunityTm-WAP49Trichuriasisvaccine

Identifiers

PMID35197976
PMCPMC8859434
OpenAlexW4210858213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.